Inclacumab

N/A

Report date: 2025/12/18 16:22:39

Base Information

Drug NameInclacumab
Drug Alias Nameinclacumabum英拉苏单抗英拉库人单抗DSM-ACC-2641RO-4905417 +[12] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionImmunostimulantsP-selectin inhibitors
TargetsP-selectin
Therapy Area/IndicationsPainGraft Occlusion, VascularAnemia, Sickle Cell +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaZambiaUnited States +[20] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesGenmab A/SF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesPfizer Inc
Inactive CompaniesF. Hoffmann-La Roche Ltd
Active IndicationsPain
Inactive IndicationsGraft Occlusion, VascularAnemia, Sickle CellPeripheral Arterial Disease +[4] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG